Cwm LLC Has $1.82 Million Position in Bruker Corporation (NASDAQ:BRKR)

CWM LLC raised its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 156.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,596 shares of the medical research company's stock after purchasing an additional 26,582 shares during the quarter. CWM LLC's holdings in Bruker were worth $1,820,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. London Co. of Virginia raised its position in shares of Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after acquiring an additional 1,843,294 shares during the last quarter. Brown Advisory Inc. grew its stake in shares of Bruker by 18.9% during the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock worth $100,599,000 after purchasing an additional 383,425 shares during the period. Geode Capital Management LLC grew its stake in shares of Bruker by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock worth $118,081,000 after purchasing an additional 20,273 shares during the period. FIL Ltd grew its stake in shares of Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after purchasing an additional 1,420,102 shares during the period. Finally, Sculptor Capital LP grew its stake in Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after acquiring an additional 1,420,569 shares during the period. Institutional investors own 79.52% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on BRKR shares. Wells Fargo & Company decreased their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Stifel Nicolaus reduced their price target on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research report on Thursday, May 8th. The Goldman Sachs Group reduced their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. UBS Group dropped their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Finally, Bank of America decreased their price objective on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Bruker has a consensus rating of "Hold" and an average price target of $52.89.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien acquired 2,608 shares of the business's stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the acquisition, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. The trade was a 0.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 27.30% of the stock is currently owned by company insiders.

Bruker Price Performance

Bruker stock traded up $1.11 during mid-day trading on Wednesday, reaching $39.91. 4,022,183 shares of the company were exchanged, compared to its average volume of 1,850,834. The firm has a market cap of $6.05 billion, a PE ratio of 76.75, a PEG ratio of 2.61 and a beta of 1.18. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.57 and a quick ratio of 0.74. Bruker Corporation has a 12 month low of $34.10 and a 12 month high of $72.94. The company has a fifty day simple moving average of $39.34 and a 200-day simple moving average of $44.58.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The firm had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. During the same period in the prior year, the company posted $0.53 earnings per share. The business's revenue for the quarter was up 11.0% on a year-over-year basis. As a group, equities research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 annualized dividend and a dividend yield of 0.50%. Bruker's payout ratio is 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.